Cargando…

DNA Methylation and the HOXC6 Paradox in Prostate Cancer

Overexpression of the classical homeobox transcription factor HOXC6 is frequent in prostate cancers and correlates with adverse clinical parameters. Since surprisingly many HOXC6 target genes are downregulated in prostate cancer, it has been posited that oncogenic effects of HOXC6 in prostate cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Vinarskaja, Anna, Yamanaka, Masanori, Ingenwerth, Marc, Schulz, Wolfgang A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Molecular Diversity Preservation International (MDPI) 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3763392/
https://www.ncbi.nlm.nih.gov/pubmed/24213107
http://dx.doi.org/10.3390/cancers3043714
_version_ 1782283006311923712
author Vinarskaja, Anna
Yamanaka, Masanori
Ingenwerth, Marc
Schulz, Wolfgang A.
author_facet Vinarskaja, Anna
Yamanaka, Masanori
Ingenwerth, Marc
Schulz, Wolfgang A.
author_sort Vinarskaja, Anna
collection PubMed
description Overexpression of the classical homeobox transcription factor HOXC6 is frequent in prostate cancers and correlates with adverse clinical parameters. Since surprisingly many HOXC6 target genes are downregulated in prostate cancer, it has been posited that oncogenic effects of HOXC6 in prostate cancer may be unmasked by concurrent epigenetic downregulation of target genes exerting tumor suppressive effects. To test this hypothesis, we have studied the expression of three HOXC6 target genes, CNTN1 (encoding a cell adhesion protein), DKK3 and WIF1 (encoding WNT growth factor antagonists) as well as DNA methylation of DKK3 and WIF1. HOXC6 upregulation and association with poor prognosis were confirmed in our tissue series. The three target genes were each significantly downregulated in cancer tissues and expression of each one correlated inversely with that of HOXC6. Cases with lower WIF1 expression showed significantly earlier recurrence (p = 0.021), whereas no statistical significance was reached for CNTN1 and DKK3. Hypermethylation of DKK3 or WIF1 gene promoters was observed in a subset of cancers with downregulated expression, but was often weak. Our data support the hypothesis that HOXC6 target genes exerting tumor-suppressive effects are epigenetically downregulated in prostate cancer, but DNA methylation appears to follow or bolster rather than to cause their transcriptional inactivation.
format Online
Article
Text
id pubmed-3763392
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Molecular Diversity Preservation International (MDPI)
record_format MEDLINE/PubMed
spelling pubmed-37633922013-09-05 DNA Methylation and the HOXC6 Paradox in Prostate Cancer Vinarskaja, Anna Yamanaka, Masanori Ingenwerth, Marc Schulz, Wolfgang A. Cancers (Basel) Article Overexpression of the classical homeobox transcription factor HOXC6 is frequent in prostate cancers and correlates with adverse clinical parameters. Since surprisingly many HOXC6 target genes are downregulated in prostate cancer, it has been posited that oncogenic effects of HOXC6 in prostate cancer may be unmasked by concurrent epigenetic downregulation of target genes exerting tumor suppressive effects. To test this hypothesis, we have studied the expression of three HOXC6 target genes, CNTN1 (encoding a cell adhesion protein), DKK3 and WIF1 (encoding WNT growth factor antagonists) as well as DNA methylation of DKK3 and WIF1. HOXC6 upregulation and association with poor prognosis were confirmed in our tissue series. The three target genes were each significantly downregulated in cancer tissues and expression of each one correlated inversely with that of HOXC6. Cases with lower WIF1 expression showed significantly earlier recurrence (p = 0.021), whereas no statistical significance was reached for CNTN1 and DKK3. Hypermethylation of DKK3 or WIF1 gene promoters was observed in a subset of cancers with downregulated expression, but was often weak. Our data support the hypothesis that HOXC6 target genes exerting tumor-suppressive effects are epigenetically downregulated in prostate cancer, but DNA methylation appears to follow or bolster rather than to cause their transcriptional inactivation. Molecular Diversity Preservation International (MDPI) 2011-09-27 /pmc/articles/PMC3763392/ /pubmed/24213107 http://dx.doi.org/10.3390/cancers3043714 Text en © 2011 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Article
Vinarskaja, Anna
Yamanaka, Masanori
Ingenwerth, Marc
Schulz, Wolfgang A.
DNA Methylation and the HOXC6 Paradox in Prostate Cancer
title DNA Methylation and the HOXC6 Paradox in Prostate Cancer
title_full DNA Methylation and the HOXC6 Paradox in Prostate Cancer
title_fullStr DNA Methylation and the HOXC6 Paradox in Prostate Cancer
title_full_unstemmed DNA Methylation and the HOXC6 Paradox in Prostate Cancer
title_short DNA Methylation and the HOXC6 Paradox in Prostate Cancer
title_sort dna methylation and the hoxc6 paradox in prostate cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3763392/
https://www.ncbi.nlm.nih.gov/pubmed/24213107
http://dx.doi.org/10.3390/cancers3043714
work_keys_str_mv AT vinarskajaanna dnamethylationandthehoxc6paradoxinprostatecancer
AT yamanakamasanori dnamethylationandthehoxc6paradoxinprostatecancer
AT ingenwerthmarc dnamethylationandthehoxc6paradoxinprostatecancer
AT schulzwolfganga dnamethylationandthehoxc6paradoxinprostatecancer